RxDoctor Payments Data

Stephen Higgins, MD

Ophthalmology · Portage, MINPI 1235104845

Payments from drug & device makers

$994in general payments, 2019–2025

Across 40 payments — averaging $24.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$477
  • Omeros Corporation$120
  • Ocular Therapeutix, Inc.$79
  • Tearlab Corp$61
  • Novartis$58
  • Tarsus Pharmaceuticals, Inc.$40
  • plus $159 from 7 others

What the payments were for

  • Food & beverage$994100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$994 in reported general payments places this provider in the 45th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$258,356
Medicare patients
664
Services billed
1,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine24$37,904
Prednisolone Acetate688$21,463
Latanoprost740$13,683
BromsiteBromfenac Sodium50$12,807
MoxifloxacinMoxifloxacin Hcl710$10,927
Brimonidine Tartrate65$9,576
Timolol Maleate157$7,706
LumiganBimatoprost13$6,419
Cyclosporine20$5,964
Fluorometholone70$5,846
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat171$4,686
SimbrinzaBrinzolamide/Brimonidine Tart19$4,124
Loteprednol Etabonate30$3,406
Travoprost22$3,278
Bromfenac Sodium14$2,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$26$44,32337 claims
Sun Pharmaceutical Industries Inc.Bromsite$13$12,80750 claims
AlconSimbrinza$477$4,12419 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$18$3,40630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Portage

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →